Leading Beyond The Lab

ARTO Talent
  • 0.0 (0)
  • LIFE SCIENCES
  • UPDATED WEEKLY

97% of our listeners don't realise they aren't followed, please double check, thank you! The Leading Beyond The Lab Podcast is hosted by Lawrence Rose, one of the Directors at ARTO, a talent solutions agency specialising in leadership roles within the Life Sciences sector globally. This podcast provides insightful discussions with industry experts, leaders and innovators, shaping the future in drug development and clinical devices. We talk with biotechnology and/or pharmaceutical executives, and find out from them their stories, personal career development and analyse their opinion on how to become successful in this space. We talk on a range of topics including soft skills, oncology, leadership, micromanagement, investment, cardiology, AI, dementia, addiction, hematology, dermatology, and much more. This podcast applies broadly to all types of connections in the Life Sciences Industry, and aims to educate and inspire those who want to excel in leadership.  Hosted on Acast. See acast.com/privacy for more information.

  1. AI Is About to Simulate Human Biology - Bioptimus

    22H AGO

    AI Is About to Simulate Human Biology - Bioptimus

    95% of our viewers aren’t subscribed. If you’re watching and not yet subscribed, please subscribe to the channel so you don’t miss future episodes. Can AI become a universal simulator of biology, helping predict disease, improve drug success rates, and reshape how medicine is developed? This week on Leading Beyond The Lab, Lawrence Rose sat down with Jean-Philippe Vert, Co-Founder and CEO of Bioptimus, with decades of experience spanning artificial intelligence, computational biology, academia and big tech, including leadership roles at Google, and work influenced by breakthroughs such as DeepMind’s AlphaFold. In this episode, Jean-Philippe covers: • Why Bioptimus is focused on understanding patient biology, not simply designing molecules, and why that could change drug development. • How AI-powered decision systems could improve translational research, clinical trial design, patient recruitment and disease prediction. • Why Jean-Philippe left Google to build Bioptimus, and why foundation models for biology may represent a major shift in medicine. • How partnerships across healthcare systems, pharma and research institutions are helping build the data infrastructure behind biological foundation models, with perspectives shaped alongside leaders including Sarah Teichmann (Professor at Cambridge University) and Caroline Uhler (Professor at MIT) • What makes AI in biology defensible, from proprietary data partnerships and elite interdisciplinary teams, to support from investors including Edward Kliphuis (Sofinnova Partners), Bpifrance, Cathay Investments. A thoughtful conversation on AI, biology, and the future of medicine. From lessons learned in big tech to what it takes to build enduring platforms in TechBio, this is a considered discussion for anyone interested in where scientific discovery is heading. Be sure to check out the full episode. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent TikTok: https://www.tiktok.com/@artotalent Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com/ Youtube: https://www.youtube.com/@artotalent Jean-Philippe Vert CEO at Bioptimus LinkedIn: https://www.linkedin.com/in/jean-philippe-vert/ Lawrence Rose Talent Solutions Director at ARTO LinkedIn: https://www.linkedin.com/in/lawrencerose/ Timestamps 00:00 Introduction and vision for AI as a universal simulator of biology 01:41 Introducing Jean-Philippe Vert and @Bioptimus 02:27 What Bioptimus is doing differently in AI biology 07:46 AI decision systems and improving clinical development 12:52 Early disease detection and predictive healthcare 15:28 Why Jean-Philippe left @Google 19:21 Building and sourcing biological data at scale 22:19 Partnerships and foundation models 28:04 Lessons from big tech 33:23 Defensibility in AI biology 37:09 Building interdisciplinary teams and culture 39:28 AI in healthcare, hype versus infrastructure 41:20 What AI means for doctors 43:10 What may define lasting AI-biology companies 45:05 Challenges of building Bioptimus 48:13 Prioritisation and deciding where to focus 51:33 Mentorship, leadership and building teams 53:02 Communicating vision to boards and investors 55:33 What success looks like in ten years #LeadingBeyondTheLab #ARTOTalent #TechBio #ArtificialIntelligence #DrugDiscovery #ComputationalBiology #PrecisionMedicine Hosted on Acast. See acast.com/privacy for more information.

    56 min
  2. I Built A Billion-Dollar Company, Lost It All... Then Built Another 5 - Robert Wessman

    APR 28

    I Built A Billion-Dollar Company, Lost It All... Then Built Another 5 - Robert Wessman

    What does it take to build not just one billion-dollar company, but seven and start again after losing it all? In this episode, Robert Wessman shares the mindset, discipline and foresight behind building one of the world’s most ambitious biosimilars platforms. This week on Leading Beyond The Lab, Lawrence Rose sat down with Robert Wessman, Founder and Executive Chairman, with over 25 years of experience spanning global pharmaceuticals, generics, biosimilars and serial entrepreneurship. In this episode, Robert Wessman covers: (01:12) Why biologics dominate the future of pharmaceuticals and the urgent need to expand access through biosimilars, with treatment costs reaching up to $100,000 per patient annually (04:10) Building seven companies including six unicorns, and scaling a global generics business across 80+ countries with over 16,500 employees (12:32) The seven-pillar framework behind building high-performance culture, including vision setting, team alignment and execution discipline (18:14) The importance of timing in biotech, and how starting too early or too late in biosimilars can determine success or failure (38:16) Strategic foresight in action, from anticipating regulatory changes to building one of the largest biosimilars pipelines with over 30 products This conversation offers a clear, experience-backed perspective on scaling in life sciences, building resilient organisations and making high-impact decisions in complex markets. If you are working in biotech, pharma or leadership, this episode provides practical insights worth applying. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1 Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com/ Youtube: https://www.youtube.com/@life_sciences Robert Wessman LinkedIn: https://www.linkedin.com/in/robert-wessman/ Lawrence Rose LinkedIn: https://www.linkedin.com/in/lawrencerose/ Timestamps: 00:00 Introduction 00:46 The global cost challenge of biologics 01:12 Market dynamics and future of biosimilars 03:11 Origins of building multiple pharma companies 04:10 Scaling Actavis into a global leader 05:22 Repeatable frameworks for building companies 06:53 Execution, culture and operational excellence 10:01 Building Alvotech in Iceland 11:10 Hiring globally and building culture 12:32 The seven pillars of high-performance culture 15:28 Execution and accountability at scale 17:03 Scaling rapidly while maintaining culture 18:14 Timing the biosimilars market 19:27 Fundraising and early-stage selling 22:07 Building partnerships and licensing strategy 24:21 Manufacturing strategy and infrastructure 25:49 Business development and commercial model 27:11 Building global supply chains 28:23 Transitioning leadership roles 30:29 Evolution of CEO skillsets 32:03 AI and the future of work in pharma 34:03 Hiring for high-performance teams 36:33 Managing risk and operational challenges 37:07 Reducing development costs through foresight 38:16 Scaling pipeline strategy 40:25 Patent challenges and market barriers 42:19 Anticipating market shifts in biologics 44:11 Navigating setbacks and industry challenges 45:26 Market dynamics and global pricing pressures 47:08 Why Iceland as a strategic base 50:47 Attracting global talent to Iceland 53:09 Capital markets and disciplined growth 54:40 Risks of overfunding 55:04 Personal story and adversity 58:19 Near-death cycling accident 01:00:30 Recovery and resilience 01:05:55 Impact on mindset and life perspective #LeadingBeyondTheLab #ARTOTalent #Biotech #Pharmaceuticals #Biosimilars #LifeSciences #Leadership Hosted on Acast. See acast.com/privacy for more information.

    1h 24m
  3. AI Discovering Medicines Humans Could Never Find: James Field - LabGenius Therapeutics

    APR 20

    AI Discovering Medicines Humans Could Never Find: James Field - LabGenius Therapeutics

    AI is beginning to uncover medicines that humans alone could never design. This week on another episode of Leading Beyond the Lab, we host James Field, CEO and Founder of LabGenius Therapeutics, a company pioneering the use of machine learning, robotics, and synthetic biology to engineer the next generation of therapeutic antibodies. With over a decade of experience spanning AI-driven drug discovery, protein engineering, and synthetic biology, James founded LabGenius Therapeutics to rethink how biologic medicines are discovered. In this episode, James discusses: - The founding story of LabGenius Therapeutics and how its AI-guided experimentation platform is transforming antibody engineering. - The companies backing by leading investors including Kindred Capital (Leila Zegna), Lux Capital, Obvious Ventures, M Ventures, and Octopus Ventures, and is guided by industry leaders such as Edwin Moses, the company’s Chairman and a veteran biotech executive. - LabGenius Therapeutics' collaboration with Sanofi, and how partnerships between biotech startups and global pharma companies are helping translate AI-designed antibodies into real therapeutic pipelines. - The importance of global scientific conferences such as European Society for Medical Oncology, where breakthroughs in oncology and biologics are shaping the future of therapeutic development. - The mentors and inspirations that shaped his journey into biotech, from his university lecturers at Imperial College London to industry leaders like Edwin Moses, who now serves as Chairman of LabGenius Therapeutics and has played a key role in guiding the company’s growth. If you're interested in AI-driven drug discovery, biotech entrepreneurship, and the future of medicine, this episode is one you won’t want to miss. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1 Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com/ Youtube: https://www.youtube.com/@artotalent Dr. James Field LinkedIn: https://www.linkedin.com/in/james-field-7518a05b/ Lawrence Rose Co-Founder + Talent Solutions Director At ARTO LinkedIn: https://www.linkedin.com/in/lawrencerose/ Timestamps: 02:40 Rewriting the Rules of Drug Discovery 16:21 Scaling Innovation 37:29 AI, Motivation & Purpose Hosted on Acast. See acast.com/privacy for more information.

    47 min
  4. Will the Drug Work? Engineering a New Future for Oncology - BioCortex

    MAR 3

    Will the Drug Work? Engineering a New Future for Oncology - BioCortex

    90% of our listeners don't realise they aren't subscribed - please check! What if we could predict whether a drug will work, before it ever reaches a patient? This week, in another episode of Leading Beyond the Lab, we host a co-guest episode featuring Nik Sharma, CEO & Co-Founder of BioCortex, a trained neurologist with years of experience spanning clinical medicine, ALS research, academia (Cambridge, NIH) and more. And Muhannad Alomari, CTO & Co-Founder, with over a decade of experience spanning aerospace engineering, AI leadership and physics-based systems modelling. In this episode, the duo covers: Why bacteria inside tumours may explain clinical trial variability, how “in silico bridge trials” could reshape oncology development, and how BioCortex plans to translate that science into commercial inflection points, global licensing models, and long-term value creation without taking traditional pipeline risk.From partnerships with CD BioPharma, they explain how global clinical strategy, particularly leveraging innovation and trial infrastructure emerging from China, is reshaping how oncology assets are advanced and positioned for global success.They also discuss investor backing from Edward Kliphuis from Sofinnova, Hussein Kanji from Hoxton Ventures and Draper Associates, and how capital discipline combined with deep-tech engineering principles (inspired by Rolls-Royce and even NASA) is shaping a new model for oncology drug development.They also reflect on visiting leading oncology centres in China alongside HSBC and AstraZeneca, highlighting the sheer scale and speed of patient recruitment, momentum that was clearly visible in multiple back-to-back presentations at ASCO, signalling a structural shift in global cancer innovation. This is a conversation about speed, probability, biology, engineering, and ultimately, time. Because for patients, time is everything. To listen to (or watch) the full episode, search “Leading Beyond the Lab BioCorteX” on wherever you get your podcasts, or click on the first link in the comments below. Hosted on Acast. See acast.com/privacy for more information.

    58 min
  5. A Single Injection set to Eliminate Cancer? CEO of Candel Therapeutics - Paul Peter Tak

    FEB 24

    A Single Injection set to Eliminate Cancer? CEO of Candel Therapeutics - Paul Peter Tak

    What if a single injection could teach the immune system to eliminate cancer, and keep it away? This week, in another episode of Leading Beyond the Lab, Lawrence Rose sits down with Paul Peter Tak, MD, PhD, FMedSci, President & CEO of Candel Therapeutics, one of the most quietly compelling stories in cancer immunotherapy today. With over 30 years of experience spanning academic medicine, clinical immunology, rheumatology, oncology, and global pharmaceutical leadership, Paul Peter brings a rare clinician-scientist perspective to biotech leadership. Prior to Candel, he served as Chief Immunology Officer and Global Head of Development at GSK (led by Luke Miels) , where he helped shape immunology and oncology strategy at scale. Paul Peter is also founder and previous chair of the dept of clinical immunology and rheumatology at Amsterdam UMC. In this episode, Paul Peter covers: - The mission behind Candel Therapeutics and why viral immunotherapy represents a fundamentally new modality, shifting the goal from helping patients live longer with cancer to helping them live without cancer. - Why Candel’s lead programs (including CAN-2409) are gaining serious scientific credibility, supported by leaders such as Nobel laureate James P. Allison and the "father of CAR-T cell therapy" Carl June, and how this external validation is changing industry and investor perception. - Lessons from past paradigm shifts in medicine, drawing on his early academic work at Leiden University, where once-dismissed antibody therapies later became standard of care, a parallel to today’s scepticism around viral immunotherapy. - How leadership, culture, and decision-making drive biotech success, shaped by his experience building teams in academia, transforming R&D at GSK, and learning large-scale leadership from mentors like Lord Patrick Vallance. - Why flexible operating models matter in biotech, including Candel’s approach to commercialisation through partners such as IDEA Pharma (led by Mike Rea) and Globe Life Sciences (Jonathon Mitchell), and cautionary lessons from companies like Oncorus and Replimune. Be sure to check out this episode to hear how Paul-Peter Tak is helping redefine what’s possible in cancer immunotherapy - and what it takes to lead beyond the lab. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1 Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Youtube: https://www.youtube.com/@life_sciences Website: https://arto-talent.com Paul Peter Tak CEO at Candel Therapeutics LinkedIn: https://www.linkedin.com/in/paul-peter-tak-md-phd-fmedsci-1b44749/ Lawrence Rose Co-Founder + Talent Solutions Director At ARTO LinkedIn: https://www.linkedin.com/in/lawrencerose/ Timestamps: 01:50 Candel's Mission 19:51 The US Promising Future for Candel 35:44 Culture at Candel 40:44 Paul Peter's Motivations as CEO Hosted on Acast. See acast.com/privacy for more information.

    1h 1m
  6. Is AI About to Collapse the Cost of Healthcare — Or Is This Another Tech Bubble? | Edward Kliphuis

    FEB 3

    Is AI About to Collapse the Cost of Healthcare — Or Is This Another Tech Bubble? | Edward Kliphuis

    If AI is collapsing the cost of healthcare — are we on the brink of a historic breakthrough… or another bubble? This week on Leading Beyond the Lab, we sit down with @Edward Kliphuis, Partner at @Sofinnova Partners, one of Europe’s leading life-sciences venture capital firms. With over 20 years of experience spanning venture capital, digital health, tech-bio investing, and global life-sciences strategy, Edward has been at the forefront of investing where biology, computation, and healthcare collide. In this episode, Edward covers: - What’s genuinely different about AI in drug discovery and digital medicine today, and how collapsing healthcare costs could unlock a $10 trillion opportunity by reshaping long-term global supply–demand dynamics. - Edward explains how @Excelsior, backed by Sofinnova Partners, @Khosla Ventures and @Deerfield Management, and led by @Mike Foley, is using an AI-driven, modular chemistry platform, originating from @Marty Burke at the @University of Illinois, to create entirely new, de novo small-molecule drugs. - Why the US pharma & tech landscape may resemble a bubble, or a once-in-a-generation inflection point - He talks about @Latent Labs, (led by @Simon Kohl) a Sofinnova-backed company designing entirely new proteins that do not exist in nature, unlocking new therapeutic possibilities. - Edward outlines Sofinnova’s investment in @Bioptimus and discusses @Moon Surgical, exploring how AI and robotics are improving drug discovery and augmenting clinicians in complex procedures. - Edward reflects on the broader AI landscape, referencing an @HSBC investment banking report questioning the long-term economics underpinning large AI models such as @OpenAI, before highlighting comments from @Geoffrey Hinton on the scalability limits of current AI architectures. From AI-driven drug discovery and robotics in surgery, to healthcare economics, venture capital philosophy, and Europe vs the US innovation gap, this is a deep, unfiltered look at where life sciences is heading next. To listen to (or watch) the full episode, search "Leading Beyond The Lab Edward Kliphuis" on your preferred streaming platform, or click on the first link in the comments below! Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1 Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Youtube: https://www.youtube.com/@life_sciences Website: https://arto-talent.com Edward Kliphuis Partner at Sofinnova Partners LinkedIn: https://www.linkedin.com/in/ekliphuis/ Lawrence Rose Co-Founder + Talent Solutions Director At ARTO LinkedIn: https://www.linkedin.com/in/lawrencerose/ Timestamps: 00:00 Sofinnovas Partner's Investments 17:41 The US Pharma "Bubble" & AI 28:02 Investing in the Right CEO / Company Hosted on Acast. See acast.com/privacy for more information.

    41 min
  7. Parkinson’s Breakthrough Could Be Just Around the Corner | BlueRock Therapeutics

    JAN 29

    Parkinson’s Breakthrough Could Be Just Around the Corner | BlueRock Therapeutics

    From science fiction to clinical reality. What happens when cell therapy moves from promise to proof in patients who have run out of options? This week on Leading Beyond the Lab, Lawrence Rose sat down with Amit Rakhit, Chief Medical Officer at BlueRock Therapeutics, to explore how regenerative medicine, leadership, and culture intersect at the most pivotal stages of biotech development. A physician by training, Amit has built his career across large pharma and early stage biotech, including experience at Bristol Myers Squibb and Biogen, working on programmes ranging from rare disease to neurodegeneration. He is also a visible advocate for authenticity and inclusion within the life sciences industry. In this episode, Amit covers: • How BlueRock Therapeutics is translating the promise of cell therapy into real clinical trials for Parkinson’s disease, and why this moment is so significant for patients who have exhausted existing treatments (01:09) • What it takes to balance bold scientific vision with realism, credibility, and execution when leading clinical programmes at a pivotal stage (03:29) • The real differences between CEO and CMO roles, why leadership is not about hierarchy, and how self-awareness shapes long-term career impact (04:58) • Why authenticity, diversity of thought, and culture consistently separate successful biotechs from those that struggle, more than metrics alone (06:37) • Lessons from a career spanning programmes such as Plavix and Spinraza at Biogen, and what physician scientists should consider when transitioning into industry roles (12:00) If you want to understand how science, leadership, and empathy come together to shape medicines that can truly change lives, this is an episode worth your time. Check out the full conversation and hear directly from one of the industry’s most thoughtful clinical leaders. Follow ARTO: https://linktr.ee/arto_talent Amit Rakhit LinkedIn: https://www.linkedin.com/in/amit-rakhit/ Lawrence Rose LinkedIn: https://www.linkedin.com/in/lawrencerose/ Timestamps: 00:00 Introduction and background 01:09 Cell therapy and BlueRock Therapeutics’ mission 03:29 Leadership, credibility, and execution 04:58 CEO vs CMO roles in biotech 06:37 Authenticity, inclusion, and culture 09:24 What separates successful biotechs 12:00 Physician scientists transitioning into industry 18:34 Career-defining moments and resilience 22:38 The future of cell therapy and emerging modalities 24:32 AI in drug discovery and clinical development 26:26 Closing thoughts and where to connect #LeadingBeyondTheLab #ARTOTalent #CellTherapy #BiotechLeadership #RegenerativeMedicine #LifeSciences #ClinicalDevelopment Hosted on Acast. See acast.com/privacy for more information.

    29 min
  8. How Smart Capital Is Shaping the Future of Biotech - Jonathan Tobin

    JAN 20

    How Smart Capital Is Shaping the Future of Biotech - Jonathan Tobin

    97% of our viewers don't realise they aren't followed, please double check, thank you! What does it really take to back and build world-class biotech companies from idea to FDA approval? This week on Leading Beyond the Lab, Lawrence Rose sat down with Jonathan Tobin, Partner at Brandon Capital, to explore what truly drives success in life-science venture capital. With over 20 years' experience spanning biotech investment, company creation, board leadership, and early-stage venture building, Jonathan has played a key role in building and scaling biotech companies across Europe, Australia and the US. In this episode Jonathan covers: - How Brandon Capital was co-founded in Australia by Chris Nave and Stephen Thompson, who grew it into a globally respected life sciences VC firm spanning company creation, long-term funding, and expansion in the US and UK. - Jonathan reflects on how Brandon Capital has helped shape the Australian biotech ecosystem over the last almost 2 decades. - Investments like AstronauTx, AdvanCell, Myricx Bio, and the stories from the frontline, including strategic pivots, tough decisions, successful exits, and the high-conviction bets that shaped portfolio outcomes. - Practical, investor-led advice for founders raising venture capital; covering readiness, storytelling, common mistakes, and how to stand out in competitive funding rounds. - How CatalYm has progressed deep into the clinic, and why Brandon Capital has supported the company through multiple funding rounds. - Jonathan’s outlook on the future of biotech, from neuroscience and radiopharmaceuticals, to overlooked white-space opportunities shaping the next innovation cycle. Be sure to check out the full episode of Leading Beyond the Lab, and don’t forget to like, subscribe, and share with anyone building in biotech. To listen to (or watch) the full episode, search "Leading Beyond The Lab Jonathan Tobin" on your preferred streaming platform. Hosted on Acast. See acast.com/privacy for more information.

    44 min
See All (33)

About

97% of our listeners don't realise they aren't followed, please double check, thank you! The Leading Beyond The Lab Podcast is hosted by Lawrence Rose, one of the Directors at ARTO, a talent solutions agency specialising in leadership roles within the Life Sciences sector globally. This podcast provides insightful discussions with industry experts, leaders and innovators, shaping the future in drug development and clinical devices. We talk with biotechnology and/or pharmaceutical executives, and find out from them their stories, personal career development and analyse their opinion on how to become successful in this space. We talk on a range of topics including soft skills, oncology, leadership, micromanagement, investment, cardiology, AI, dementia, addiction, hematology, dermatology, and much more. This podcast applies broadly to all types of connections in the Life Sciences Industry, and aims to educate and inspire those who want to excel in leadership.  Hosted on Acast. See acast.com/privacy for more information.

Information

  • Creator
    ARTO Talent
  • Years Active
    2024 - 2026
  • Episodes
    33
  • Rating
    Clean
  • Copyright
    © ARTO Talent
  • Show Website
    Leading Beyond The Lab

You Might Also Like